Nausea and Vomiting

Researchers are looking at new ways to deliver some antiemetics for managing chemotherapy-induced nausea and vomiting (CINV). The 5-HT3 receptor antagonist granisetron is available orally and now as a transdermal patch. Studies have shown that the patch, which is placed on a patient’s skin 24–48 hours before chemotherapy, is just as effective as the oral capsule, which will be beneficial for patients who are unable to swallow pills (Hawkins & Grunberg, 2009).
Category:
Estimates suggest that more than 70% of patients receiving chemotherapy will experience at least some level of chemotherapy-induced nausea and vomiting (CINV) (Rogers & Blackburn, 2010). For patients, CINV is among the most feared and distressing side effects, yet many healthcare providers underestimate its toll and severity and therefore manage it inadequately.
Category:
Two brief ONS slideshows review the basics of chemotherapy-induced nausea and vomiting (CINV). The first provides a definition and general overview of CINV, including the five types of CINV. The second is a three-minute refresher discussing the pathophysiology of CINV, including the neurologic pathways involved.
Category:
Category:
Category:
Category:
Category:
Category:
Category:
Category:
Category:
Category:

Pages

Menu